Senseonics has filed to obtain CE Mark registration for its one-year continuous glucose monitoring (CGM) system, Eversense ...

Insulin pump market growth is propelled by advancements in technology, rising global diabetes prevalence, and increased demand for precision diabetes management.New Delhi, Feb. 06, 2025 (GLOBE ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Families want nurse or staff to monitor apps remotely in case of urgent alarms; schools cite shrinking budgets and internet ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Medha N. Munshi, MD, a geriatrician and endocrinologist at Beth Israel Deaconess Medical Center, has dedicated her career to ...

The remote patient monitoring (RPM) technology that a patient uses while receiving hospital-at-home care does not follow a ...

Lilly has taken a non-exclusive license to deploy Dexcom’s CGM systems – which include app-based remote monitoring and alarm functions – in pen- and pump-based insulin systems that form the ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.